Established in 2007, the Southern California Thyroid Cancer Consortium (SCThyCC) is a network of thyroid cancer specialists serving the large, ethnically and socially diverse thyroid cancer population in Southern California (greater Los Angeles, Irvine, Newport Beach, San Diego). The consortium is comprised of physician-investigators at major academic, public and private institutions with a focus on thyroid cancer.
We connect thyroid cancer patients with leading-edge clinical trials that offer new diagnostic tools and treatment options not typically available through local medical practices in Southern California.
The Southern California Thyroid Cancer Consortium is committed to:
- Forming research partnerships with the National Cancer Institute, other national and international thyroid cancer centers as well as private industry.
- An innovative and multidisciplinary approach to thyroid cancer which includes the specialties of endocrinology, oncology, surgery, pathology, nuclear medicine, and radiology.
- A high level of collegiality.
Clinical Trials
For available solid tumor basket trials please e-mail us at [email protected] or call 310-222-8172.
Active Trials
- Phase 3 Trial Comparing Loxo-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
- Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
- Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
- Study of Cabozantinib Compared with Placebo in Subjects with Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy
- Phase 1/2 Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-positive Solid Tumors, and Medullary Thyroid Cancer
- Phase I Study of BLU-667 (highly selective RET inhibitor) for MTC and PTC
- Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer
- Phase II Clinical Trial for Tipifarnib for HRAS-mutant Thyroid Cancer
- Active Surveillance of Papillary Thyroid Microcarcinoma
Completed Trials
- Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
- EISAI E7080- Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine Refractory Unresectable Differentiated Thyroid Cancer Stratified by Histology
- Double-blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-refractory Differentiated Thyroid Cancer
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer
- Study of RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
- Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
- Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to Assess the Efficacy and Safety of Vandetanib (Caprelsa) 300 mg in Patients with Differentiated Thyroid Cancer that is Either Locally Advanced or Metastatic
- RIFTOS MKI (Observational) Radioactive Iodine Refractory Asymptomatic Patients in Differentiated Thyroid cancer: An Observational Study to Assess the Use of MultiKinase Inhibitors
- Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Meet Our Team
CONSORTIUM CHAIR
Jerome M. Hershman, MD
Distinguished Professor of Medicine, David Geffen School of Medicine at UCLA
CONSORTIUM SECRETARY
Andrew G. Gianoukakis, MD
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
SCThyCC Investigators
- Inder J. Chopra, MD | UCLA
- Michael J. Demeure, MD | Hoag Hospital
- Andrew G. Gianoukakis, MD | The Lundquist Institute for Biomedical Innovation
- Jerome M. Hershman, MD | UCLA
- Angela M. Leung, MD | UCLA
- Alain Mita, MD | Cedars Sinai Medical Center
- Wendy Sacks, MD | Cedars Sinai Medical Center
- Behrouz Salehian, MD | City of Hope
- Peter A. Singer, MD | USC
- Stephanie Smooke, MD | UCLA
- Deborah L. Wong, MD | UCLA